Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bht-3009
- Development stage
- Phase 2
- Lead developer
- Bayhill Therapeutics
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
BHT-3009 is an investigational DNA vaccine that encodes full-length human myelin basic protein (MBP). It is designed to induce antigen-specific immune tolerance in patients with multiple sclerosis (MS) by altering the immune response to MBP, a key autoantigen implicated in MS pathogenesis. The drug works by delivering the MBP gene via plasmid DNA, leading to expression of MBP within antigen-presenting cells and subsequent tolerization of pathogenic T cells reactive to myelin antigens. Clinical trials have shown that BHT-3009 was safe and well tolerated, with evidence of reduced lesion activity on MRI and decreased clinical relapse rates in certain patient subgroups. However, overall efficacy results were mixed, and development for MS has been discontinued[1][2][3][4][5][6][8]. The drug was developed by Bayhill Therapeutics.
Beyond the preview
Go deeper on bht-3009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bht-3009.